<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02800941</url>
  </required_header>
  <id_info>
    <org_study_id>1608037</org_study_id>
    <secondary_id>2016-001608-41</secondary_id>
    <nct_id>NCT02800941</nct_id>
  </id_info>
  <brief_title>Bleeding Frequency Under Anticoagulant Treatment in Pulmonary Hypertension</brief_title>
  <acronym>HEMA-HTP</acronym>
  <official_title>Bleeding Frequency Under Anticoagulant Treatment in Pulmonary Hypertension : HEMA-HTP Multicentric Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary hypertension (PHT) patients often receive long term oral anticoagulants. If the
      indication is strong, in the secondary chronic thrombo-embolism pulmonary hypertension
      (CTE-PHT) prevention, the frequent prescription (50 to 90% of patients) contrasts with their
      low level of proof in the PHT. Last but not least, anticoagulants are known to be the
      principal cause of iatrogenic hospitalization (major bleeding).

      In this study, patients are all followed during one year, to determine the annual frequency
      of major bleedings (according to the International Society on Thrombosis and Haemostasis
      (ISTH) international definition). Each event notified is validated by an independent
      committee for clinical events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary hypertension (PHT) patients often receive long term oral anticoagulants. If the
      indication is strong, in the secondary chronic thrombo-embolism pulmonary hypertension
      (CTE-PHT) prevention, the frequent prescription (50 to 90% of patients) contrasts with their
      low level of proof in the PHT. Last but not least, anticoagulants are known to be the
      principal cause of iatrogenic hospitalization (bleeding).

      The only one study scaling the tolerance of anticoagulants for this population found major
      hemorrhagic levels discording with the clinical practice : really high for connectives
      associated to pulmonary arterial hypertension (PAHT), and lower in &quot;simple&quot; pulmonary
      embolism in CTE-PHT. These discoveries could belong to methodological failures of this study:
      a retrospective, monocentric one, without adjudication of events by an independent committee.
      Furthermore, there were no information about the existence of a validated indication for
      anticoagulant treatments.

      Patients are all followed during one year, to determine the annual frequency of major
      bleedings (according to the International Society on Thrombosis and Haemostasis (ISTH)
      international definition). Each event notified is validated by an independent committee for
      clinical events.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2017</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of major bleeding (according to the International Society on Thrombosis and Haemostasis definition)</measure>
    <time_frame>1 year</time_frame>
    <description>Major bleedings (according to the International Society on Thrombosis and Haemostasis definition) will be notified during one year under oral anticoagulant treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of clinically relevant bleedings</measure>
    <time_frame>1 year</time_frame>
    <description>Clinically relevant bleedings (major and non major ones) will be notified during one year under oral anticoagulant treatment.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">203</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Oral anticoagulant treatment</arm_group_label>
    <description>Patients with pulmonary hypertension are treated with oral anticoagulants according to the usual practice. Patients have follow-up at 3, 6 and 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral anticoagulant treatment</intervention_name>
    <description>The treatment is delivered according to the usual practice.</description>
    <arm_group_label>Oral anticoagulant treatment</arm_group_label>
    <other_name>warfarin (Coumadine®)</other_name>
    <other_name>fluindione (Préviscan®)</other_name>
    <other_name>acenocoumarol (Sintrom®)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Cohort of pulmonary hypertension patients receiving oral anticoagulant treatment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient insured or entitled to a social security scheme;

          -  Patient with confirmed pulmonary hypertension, followed in one of the three following
             centers: St-Etienne, Grenoble, Lyon;

          -  Pulmonary hypertension among the following etiological diagnosis: idiopathic PAH, PAH
             associated with appetite suppressants, PAH associated with connective, or Chronic
             Thrombo-embolism Pulmonary Hypertension;

          -  Patients receiving oral anticoagulants.

        Exclusion Criteria:

          -  Impossible following;

          -  Bleeding at baseline;

          -  Life expectancy of less than 3 months;

          -  Pulmonary hypertension in Group 2, Group 3 (in the absence of associated pulmonary
             embolism) and Group 5 (in the absence of associated pulmonary embolism).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent Bertoletti, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Saint-Etienne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurent Bertoletti, PhD</last_name>
    <phone>04.77.82.91.21</phone>
    <phone_ext>+33</phone_ext>
    <email>laurent.bertoletti@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carine Labruyere, CRA</last_name>
    <phone>04 77 12 04 69</phone>
    <phone_ext>+33</phone_ext>
    <email>carine.labruyere@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe Pison, MD</last_name>
      <email>christophe.pison@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe Pison, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean François Mornex, MD</last_name>
      <email>jean-francois.mornex@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Jean François Mornex, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent Cottin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Saint-Etienne</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Bertoletti, PhD</last_name>
      <phone>04 77 82 91 21</phone>
      <phone_ext>+33</phone_ext>
      <email>laurent.bertoletti@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent Bertoletti, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elodie De Magalhaes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2016</study_first_submitted>
  <study_first_submitted_qc>June 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2016</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Arterial hypertension</keyword>
  <keyword>Oral anticoagulants</keyword>
  <keyword>Major bleedings</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticoagulants</mesh_term>
    <mesh_term>Acenocoumarol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

